Vaxart (VXRT) Competitors

Inovio Pharmaceuticals (NASDAQ:INO) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Does the media prefer INO or VXRT?

In the previous week, Inovio Pharmaceuticals had 18 more articles in the media than Vaxart. MarketBeat recorded 27 mentions for Inovio Pharmaceuticals and 9 mentions for Vaxart. Vaxart's average media sentiment score of 0.74 beat Inovio Pharmaceuticals' score of 0.12 indicating that Vaxart is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inovio Pharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	10 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vaxart	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts recommend INO or VXRT?

Inovio Pharmaceuticals currently has a consensus price target of $38.00, suggesting a potential upside of 857.18%. Vaxart has a consensus price target of $3.00, suggesting a potential upside of 393.58%. Given Inovio Pharmaceuticals' higher possible upside, equities research analysts clearly believe Inovio Pharmaceuticals is more favorable than Vaxart.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inovio Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.60
Vaxart	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher valuation and earnings, INO or VXRT?

Vaxart has higher revenue and earnings than Inovio Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inovio Pharmaceuticals	$830K	124.84	-$135.12M	N/A	N/A
Vaxart	$7.38M	14.61	-$82.46M	-$0.41	-1.48

Does the MarketBeat Community prefer INO or VXRT?

Inovio Pharmaceuticals received 409 more outperform votes than Vaxart when rated by MarketBeat users. Likewise, 71.19% of users gave Inovio Pharmaceuticals an outperform vote while only 65.54% of users gave Vaxart an outperform vote.

Company	Underperform	Outperform
Inovio Pharmaceuticals	Outperform Votes 719 71.19%	Underperform Votes 291 28.81%
Vaxart	Outperform Votes 310 65.54%	Underperform Votes 163 34.46%

Which has more volatility and risk, INO or VXRT?

Inovio Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.7, meaning that its stock price is 30% less volatile than the S&P 500.

Do insiders & institutionals believe in INO or VXRT?

26.8% of Inovio Pharmaceuticals shares are held by institutional investors. Comparatively, 18.1% of Vaxart shares are held by institutional investors. 2.5% of Inovio Pharmaceuticals shares are held by company insiders. Comparatively, 2.6% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Is INO or VXRT more profitable?

Inovio Pharmaceuticals has a net margin of 0.00% compared to Vaxart's net margin of -431.61%. Vaxart's return on equity of -110.46% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inovio Pharmaceuticals	N/A	-118.17%	-83.47%
Vaxart	-431.61%	-110.46%	-62.78%

Summary

Inovio Pharmaceuticals beats Vaxart on 9 of the 16 factors compared between the two stocks.